Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 1 Interventional

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

ClinicalTrials.gov ID: NCT02520245

Public ClinicalTrials.gov record NCT02520245. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 18, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patients.

Study identification

NCT ID
NCT02520245
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 1
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2015
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Last update posted
Nov 6, 2016

2015 – 2023

United States locations

U.S. sites
9
U.S. states
9
U.S. cities
9
Facility City State ZIP Site status
City of Hope National Medical Center Duarte California
Sarah Cannon Research Institute at HealthONE Denver Colorado
Washington University School of Medicine Siteman Cancer Center St Louis Missouri
Laura & Isaac Perlmutter Cancer Center New York New York
University Hospitals Case Medical Center Cleveland Ohio
Stephenson Cancer Center Oklahoma City Oklahoma
Providence Portland Medical Center Portland Oregon
Sarah Cannon Research Institute Nashville Tennessee
START South Texas Accelerated Research Therapeutics San Antonio Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02520245, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 6, 2016 · Synced Sep 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02520245 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →